» Articles » PMID: 27428362

Radiation Therapy and Cardiac Death in Long-Term Survivors of Esophageal Cancer: An Analysis of the Surveillance, Epidemiology, and End Result Database

Overview
Journal PLoS One
Date 2016 Jul 19
PMID 27428362
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Radiation therapy (RT) for esophageal cancer often results in unintended radiation doses delivered to the heart owing to anatomic proximity. Using the Surveillance, Epidemiology, and End Results (SEER) database, we examined late cardiac death in survivors of esophageal cancer that had or had not received RT.

Methods: 5,630 patients were identified that were diagnosed with esophageal squamous cell carcinoma (SCC) or adenocarcinoma (AC) from 1973-2012, who were followed for at least 5 years after therapy. Examined risk factors for cardiac death included age (≤55/56-65/66-75/>75), gender, race (white/non-white), stage (local/regional/distant), histology (SCC/AC), esophageal location (<18cm/18-24cm/25-32cm/33-40cm from incisors), diagnosis year (1973-1992/1993-2002/2003-2012), and receipt of surgery and/or RT. Time to cardiac death was evaluated using the Kaplan-Meier method. A Cox model was used to evaluate risk factors for cardiac death in propensity score matched data.

Results: Patients who received RT were younger, diagnosed more recently, had more advanced disease, SCC histology, and no surgery. The RT group had higher risk of cardiac death than the no-RT group (log-rank p<0.0001). The median time to cardiac death in the RT group was 289 months (95% CI, 255-367) and was not reached in the no-RT group. The probability of cardiac death increased with age and decreased with diagnosis year, and this trend was more pronounced in the RT group. Multivariate analysis found RT to be associated with higher probability of cardiac death (OR 1.23, 95% CI 1.03-1.47, HR 1.961, 95% CI 1.466-2.624). Lower esophageal subsite (33-40 cm) was also associated with a higher risk of cardiac death. Other variables were not associated with cardiac death.

Conclusions: Recognizing the limitations of a SEER analysis including lack of comorbidity accountability, these data should prompt more definitive study as to whether a possible associative effect of RT on cardiac death could potentially be a causative effect.

Citing Articles

Role of Cancer History in Cardiovascular Mortality Among Different Age-group Patients With Differentiated Thyroid Cancer.

Qiu H, Zhou W, Huang Q, Lin H, Zhou Y, Wu C J Endocr Soc. 2024; 9(1):bvae213.

PMID: 39669653 PMC: 11635452. DOI: 10.1210/jendso/bvae213.


Moving beyond mean heart dose: The importance of cardiac substructures in radiation therapy toxicity.

Bowen Jones S, Marchant T, Saunderson C, McWilliam A, Banfill K J Med Imaging Radiat Oncol. 2024; 68(8):974-986.

PMID: 39228181 PMC: 11686456. DOI: 10.1111/1754-9485.13737.


From guidelines to radiology practice: navigating the 2023 ASCO guidelines for advanced gastroesophageal cancer and beyond.

Tippareddy C, Martinez O, Benza A, Bera K, Ramaiya N, Tirumani S Abdom Radiol (NY). 2024; 50(1):78-93.

PMID: 39123051 PMC: 11711647. DOI: 10.1007/s00261-024-04499-y.


Reirradiation With Proton Therapy for Recurrent Malignancies of the Esophagus and Gastroesophageal Junction: Results of the Proton Collaborative Group Multi-Institutional Prospective Registry Trial.

Hotca A, Sindhu K, Lehrer E, Hartsell W, Vargas C, Tsai H Adv Radiat Oncol. 2024; 9(5):101459.

PMID: 38596455 PMC: 11002543. DOI: 10.1016/j.adro.2024.101459.


Correlation between morphological parameters and dosimetric parameters of the heart and spinal cord in the intermediate- and advanced-stage esophageal cancer.

Zhao W, Lan L, Xu B, Chen D, Zeng Y, Guo F Cancer Rep (Hoboken). 2024; 7(3):e2015.

PMID: 38488482 PMC: 10941519. DOI: 10.1002/cnr2.2015.


References
1.
Verma V, Mishra M, Mehta M . A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016; 122(10):1483-501. DOI: 10.1002/cncr.29882. View

2.
van Nimwegen F, Schaapveld M, Cutter D, Janus C, Krol A, Hauptmann M . Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J Clin Oncol. 2015; 34(3):235-43. DOI: 10.1200/JCO.2015.63.4444. View

3.
Kole T, Aghayere O, Kwah J, Yorke E, Goodman K . Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 2012; 83(5):1580-6. DOI: 10.1016/j.ijrobp.2011.10.053. View

4.
Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy T . A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335(7):462-7. DOI: 10.1056/NEJM199608153350702. View

5.
Eley J, Friedrich T, Homann K, Howell R, Scholz M, Durante M . Comparative Risk Predictions of Second Cancers After Carbon-Ion Therapy Versus Proton Therapy. Int J Radiat Oncol Biol Phys. 2016; 95(1):279-286. PMC: 4844193. DOI: 10.1016/j.ijrobp.2016.02.032. View